Education and Training
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Contrast-enhanced Magnetic Resonance Imaging
- procedure: Magnetic Resonance Imaging
- procedure: Positron Emission Tomography
- drug: Fludeoxyglucose F-18
- drug: Fluorine F 18 Sodium Fluoride
Eligibility
Inclusion Criteria:
- Provides written informed consent
- Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223
dichloride)
- Able to remain still for duration of the imaging procedure (about one hour)
Exclusion Criteria:
- Metallic implants
Ages Eligible for Study
19 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Omar Rutledge
650-721-4089
Not Recruiting